Lifeboat Foundation

Summary: Study reveals a hidden order in seemingly random connections between neurons.

Source: University Hospital Bonn.

In the brain, our perception arises from a complex interplay of neurons that are connected via synapses. But the number and strength of connections between certain types of neurons can vary.

Alector, a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, has announced the initiation of the first-in-human Phase 1 trial of AL044. The study is investigating the safety profile, pharmacokinetics (PK), pharmacodynamics (PD) and target engagement of AL044 in healthy adults.

Longevity. Technology: Headquartered in South San Francisco, California, Alector is aiming to develop an unmatched pipeline of novel potential medicines based on insights into immunology, neurology and human genetics. The company’s therapeutic candidates are intended to harness the body’s innate power to heal itself, and Alector is pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases, and innate immuno-oncology.

Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered, and is developing, a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease.

“This exoskeleton personalizes assistance as people walk normally through the real world,” said Steve Collins, associate professor of mechanical engineering who leads the Stanford Biomechatronics Laboratory, in a press release. “And it resulted in exceptional improvements in walking speed and energy economy.”

The personalization is enabled by a machine learning algorithm, which the team trained using emulators—that is, machines that collected data on motion and energy expenditure from volunteers who were hooked up to them. The volunteers walked at varying speeds under imagined scenarios, like trying to catch a bus or taking a stroll through a park.

Continue reading “This Exoskeleton Uses Machine Learning to Put a Personalized Spring in Your Step” »

The WHO said that case numbers last week were on the rise in several countries in the Americas and it stressed that a slowdown worldwide in new cases could be the “most dangerous” time in the outbreak.

WHO chief Tedros Adhanom Ghebreyesus said more than 70,000 cases have now been reported to the U.N. health agency this year, with 26 deaths.

“Globally, cases are continuing to decline, but 21 countries in the past week reported an increase in cases, mostly in the Americas, which accounted for almost 90 percent of all cases reported last week,” he told a press conference in Geneva.

Real-world data (and real-world evidence) can also play roles outside of public health emergencies like Covid and monkeypox. They can help determine the long-term effectiveness of many treatments, especially those subject to the expedited approval process, such as those used for rare diseases, and can help determine the value of drugs in general. In many cases, clinical trials are not enough to understand how well drugs really work. Janet Woodcock, the director of the FDA’s Center for Drug Evaluation and Research, has said that the clinical trial system is “broken” and that more use of real-world evidence could be an effective addition to the approval process.

The FDA has been taking steps toward using more real-world data outside of public health emergencies like Covid and monkeypox. In 2018, the agency issued guidance for use of such evidence in approving drugs. By 2021, when the FDA issued enhanced guidance on the topic, real-world evidence had been used in approving 90 medical devices and the new use of a drug, Prograf. But this is not happening enough in practice.

Failing to use real-world data means missing out not just on better understanding of the effectiveness of individual drugs but also on a chance to improve the entire pharmaceutical sector, including addressing issues like rising costs. The availability of more data on real-world outcomes from using drugs, especially gene therapies and other innovative and often very expensive treatments, would pave the way for pricing to take patient outcomes into account through approaches like value-based contracting, when health insurers base drug prices on how well drugs work in the people who take them, rather than just in premarket clinical trials.

Summary: Pain-sensing neurons in the put secrete substance P, a molecule that protects against gut inflammation and tissue damage by boosting specific microbes in the gut. In people with inflammatory bowel disease, the pain-sensing neurons are diminished and there are significant disruptions in pain-signaling genes.

Source: Weill Cornell University.

Neurons that sense pain protect the gut from inflammation and associated tissue damage by regulating the microbial community living in the intestines, according to a study from researchers at Weill Cornell Medicine.

Fast forward a couple of months and hell of a lot of drama later, and at least one of the investors in Elon Musk’s bid to buy Twitter has cold feet.

Listen now (82 min) | Moravec and Everett meet Borges and Dick in a multiverse of many simulated worlds.

It may not be as famous as the so-called “grandfather paradox,” but that doesn’t make the idea of an infinite causal loop any less troubling… or fascinating.